Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:15:47.041Z.
Calculation as of: 2026-10-06T14:15:47.041Z.
Quote observation: 2026-10-06T14:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2c805ffacfcdae638738386c116dc6e6f159143ed75419b2c785d409d5d1ab78
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$24.97M
Price/FCF Ratio
N/A
TTM Avg
242.89
3Y Avg
242.89
5Y Avg
242.89
Market Cap
$27.60M
Price/FCF Ratio
N/A
TTM Avg
87.13
3Y Avg
87.13
5Y Avg
45.44
Market Cap
$22.43M
Price/FCF Ratio
6.90
TTM Avg
13.56
3Y Avg
13.45
5Y Avg
13.45
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $25.19M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.97M | N/A | 242.89 | 242.89 | 242.89 |
| Kyntra Bio, Inc. (KYNB)vs › | $24.65M | N/A | 118.09 | 118.84 | 145.02 |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.60M | N/A | 87.13 | 87.13 | 45.44 |
| LeonaBio, Inc. (LONA)vs › | $22.52M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.43M | 6.90 | 13.56 | 13.45 | 13.45 |
| GridAI Technologies Corp. (GRDX)vs › | $28.35M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.41M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $29.44M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $19.56M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
